logo
episode-header-image
Jun 2021
11m 52s

FDA Approves Aducanumab — A Controversia...

NPR
About this episode
The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it.

For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."

You can email Short Wave at ShortWave@NPR.org.

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

NPR Privacy Policy
Up next
Jun 17
Is sewage the future of green aviation?
The war in Iran has disrupted the global fuel supply. That has sent airline prices soaring and cancelled scores of flights. This got Short Wave host Emily Kwong wondering: Could another fuel source help take us to the skies? Today on the show, we explore the chemistry and cost of ... Show More
12m 37s
Jun 16
Could air pollution make your memory worse?
Summer is here, your windows are open and the smell of…car exhaust and the latest wildfire are wafting in. This air pollution is harmful to almost every organ, including the brain. Today on Short Wave, we talk about one way air pollution may cloud your memory.Interested in more e ... Show More
10m 21s
Jun 15
Inside the lab taste-testing the world's chocolate
Could standardizing chocolate help small-scale farmers? Chocolate scientist Julien Simonis thinks it could help persuade consumers to pay for higher quality chocolate, in turn helping out these growers. Every cacao bean is different, and for a long time, there wasn't a standard w ... Show More
10m 29s
Recommended Episodes
Aug 2021
Controversial new Alzheimer's drug in the spotlight
After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More
18m 21s
Jul 2021
'Some Hope Is Better Than Having No Hope'
<p>When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.</p><p>But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ... Show More
36m 59s
May 2024
This Is a Very Weird Moment in the History of Drug Laws
<p>Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn’t entirely been a success, either.</p><p>Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift ... Show More
1h 2m
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s